Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

UNITED STATES: Costs Spike for 2nd- and 3rd-Line ARVs and Late Treatment




 

AIDSMEDS (09.19.2013) Aids Weekly Plus

The National AIDS Treatment Advocacy Project has reported on the increase in cost to treat HIV-infected individuals on second- and third-line antretrovirals (ARVs). Researchers calculated costs after reviewing data from 2007 to 2011 in the MarketScan Commercial Claims and Encounters Database and from the MarketScan Lab Database, which covered 2007 to 2010. The researchers followed 9,931 individuals in the first group, whose treatment moved from first- to third-line therapy, and 486 individuals on ARVs in the second group who provided data on CD4 counts. The researchers adjusted for factors such as AIDS diagnosis, sex, age, region of the country, and type of health insurance. Results showed that the average cost for total care of HIV-infected individuals on first-line therapy was $28,861, cost for second-line therapy was $35,805, and for third-line, $40,804. Also, the average cost to treat a patient who started treatment with more than 350 CD4 cells was $2,526 per month. Treatment for individuals who started with 100–350 CD4 cells was $2,378 per month, and for individuals with fewer than 100 CD4 cells, the price increased to $4,860 per month. The full report, “Burden of Illness in a US Commercially Insured HIV Population: Treatment Patterns and Costs,” was presented at the 53rd ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy, September 10–13, 2013, Denver. Abstract H–662.



 


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.



Information in this article was accurate in September 20, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.